In conclusion, our study offers a novel monocyte/macrophage-IL-15-CD226+ B cell axis in T1D pathogenesis, which links innate and adaptive immunity, and offers a rationale for the development of new immunotherapies for T1D. This evidence concerns the gene CD226 and type 1 diabetes mellitus.